These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34201956)

  • 1. BARD1 Autoantibody Blood Test for Early Detection of Ovarian Cancer.
    Pilyugin M; Ratajska M; Stukan M; Concin N; Zeillinger R; Irminger-Finger I
    Genes (Basel); 2021 Jun; 12(7):. PubMed ID: 34201956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical evaluation of autoantibody of splice variant of BARD1 in detection of ovarian cancer].
    Yang ZJ; Jiang YM; Yang G; Ran YL; Yang ZH; Zhang W; Zhang JQ; Pan ZM; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2008 Sep; 43(9):680-4. PubMed ID: 19087519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BARD1 serum autoantibodies for the detection of lung cancer.
    Pilyugin M; Descloux P; André PA; Laszlo V; Dome B; Hegedus B; Sardy S; Janes S; Bianco A; Laurent GJ; Irminger-Finger I
    PLoS One; 2017; 12(8):e0182356. PubMed ID: 28786985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BARD1, a possible biomarker for breast and ovarian cancer.
    Irminger-Finger I
    Gynecol Oncol; 2010 May; 117(2):211-5. PubMed ID: 19959210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer.
    Yang WL; Gentry-Maharaj A; Simmons A; Ryan A; Fourkala EO; Lu Z; Baggerly KA; Zhao Y; Lu KH; Bowtell D; Jacobs I; Skates SJ; He WW; Menon U; Bast RC;
    Clin Cancer Res; 2017 Oct; 23(19):5912-5922. PubMed ID: 28637689
    [No Abstract]   [Full Text] [Related]  

  • 6. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
    Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer.
    Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X
    Front Immunol; 2021; 12():698312. PubMed ID: 34489945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
    Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
    Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential risk factors of ovarian cancer and analysis of CA125, a biomarker used for its monitoring and diagnosis.
    Mansha M; Gill A; Thomson PC
    Mol Biol Rep; 2019 Jun; 46(3):3325-3332. PubMed ID: 31006098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
    Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
    Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
    [No Abstract]   [Full Text] [Related]  

  • 12. Summary of
    Suszynska M; Kozlowski P
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32679805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging.
    Zhu Z; Chen Z; Wang M; Zhang M; Chen Y; Yang X; Zhou C; Liu Y; Hong L; Zhang L
    J Ovarian Res; 2022 Feb; 15(1):27. PubMed ID: 35183243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Literature Review of
    Alenezi WM; Fierheller CT; Recio N; Tonin PN
    Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32726901
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Rofes P; Del Valle J; Torres-Esquius S; Feliubadaló L; Stradella A; Moreno-Cabrera JM; López-Doriga A; Munté E; De Cid R; Campos O; Cuesta R; Teulé Á; Grau È; Sanz J; Capellá G; Díez O; Brunet J; Balmaña J; Lázaro C
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33498765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BARD1: an independent predictor of survival in non-small cell lung cancer.
    Zhang YQ; Bianco A; Malkinson AM; Leoni VP; Frau G; De Rosa N; André PA; Versace R; Boulvain M; Laurent GJ; Atzori L; Irminger-Finger I
    Int J Cancer; 2012 Jul; 131(1):83-94. PubMed ID: 21815143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis.
    Dayyani F; Uhlig S; Colson B; Simon K; Rolny V; Morgenstern D; Schlumbrecht M
    Int J Gynecol Cancer; 2016 Nov; 26(9):1586-1593. PubMed ID: 27540691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of candidate serologic markers for type I and type II ovarian cancer.
    Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
    Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.